Title

Role of neuropeptides in migraine: Where do they stand in the latest expert recommendations in migraine treatment?

Authors

Authors

M. Samsam; R. Covenas; R. Ahangari; J. Yajeya;J. A. Narvaez

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abbreviated Journal Title

Drug Dev. Res.

Keywords

headache; trigeminovascular system; substance P; calcitonin gene-related; peptide; GENE-RELATED PEPTIDE; CAUDAL TRIGEMINAL NUCLEUS; RECEPTOR ANTAGONIST; BIBN4096BS; FAMILIAL HEMIPLEGIC MIGRAINE; FOS-LIKE IMMUNOREACTIVITY; VASOACTIVE INTESTINAL POLYPEPTIDE; NEUROGENIC PLASMA EXTRAVASATION; ENKEPHALIN-LIKE MATERIAL; NOCICEPTIVE DURAL INPUT; SUPERIOR SAGITTAL; SINUS; Chemistry, Medicinal; Pharmacology & Pharmacy

Abstract

Many factors have been implicated in the pathogenesis of migraine headache, including activation of the trigeminovascular system, dysfunction of: cerebral blood vessels, circulating vasoactive substances, mitochondrial energy metabolism, brain oxygenation and metabolism, platelet disorder, alterations in serotonin levels, low levels of brain tissue magnesium, altered transport of ions across the cell membrane, and inheritance and dysfunction of the brainstem periaqueductal gray matter. The headache phase of migraine is associated with cerebral vasodilation and inflammation, presumably mediated by the release of vasoactive substances and neuropeptides including CGRP (calcitonin gene-related peptide). Increased serum CGRP levels have been detected during migraine and cluster headache. One strategy to treat migraine is to inhibit the release of neuropeptides or to block their receptors. This article briefly reviews some experimental and clinical investigations focused on neuropeptide involvement in migraine.

Journal Title

Drug Development Research

Volume

68

Issue/Number

6

Publication Date

1-1-2007

Document Type

Review

Language

English

First Page

294

Last Page

314

WOS Identifier

WOS:000252349100005

ISSN

0272-4391

Share

COinS